Monday, August 05, 2019 2:24:18 PM
From today's filing...
This Confirming Statement ("Statement") confirms that the undersigned, John R.
Sylvester, has authorized, directed and designated each of Jennifer Simpson and
Barbra Keck (each a "Designee" and together, the "Designees"), or either of them
acting singly, to: (1) prepare, execute and file for and on behalf of the
undersigned with the U.S. Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 and any rule or regulation thereunder; and (2)
prepare, execute and file for and on behalf of the undersigned with the SEC and
any stock exchange or similar authority, all Forms 3, 4 and 5, including any
amendments thereto, that the undersigned is required to file as an officer
and/or director of Delcath Systems, Inc. (the "Company") in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and any rule or regulation
thereunder.
The authority of the Designees under this Statement shall continue until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and/or transactions in securities of the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Designees. The undersigned acknowledges that the Designees are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934. This Statement is not
intended to be a power of attorney as defined in the New York General
Obligations Law, Article 5, Title 15, Section 5-1501, and in the event this
Statement is determined to be a power of attorney under such statute, this
Statement shall not revoke any power of attorney previously executed by the
undersigned and shall not be revoked by any subsequent power of attorney unless
such subsequent power of attorney expressly provides that it revokes this
Statement by referring to the date and subject hereof.
This Confirming Statement ("Statement") confirms that the undersigned, John R.
Sylvester, has authorized, directed and designated each of Jennifer Simpson and
Barbra Keck (each a "Designee" and together, the "Designees"), or either of them
acting singly, to: (1) prepare, execute and file for and on behalf of the
undersigned with the U.S. Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 and any rule or regulation thereunder; and (2)
prepare, execute and file for and on behalf of the undersigned with the SEC and
any stock exchange or similar authority, all Forms 3, 4 and 5, including any
amendments thereto, that the undersigned is required to file as an officer
and/or director of Delcath Systems, Inc. (the "Company") in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and any rule or regulation
thereunder.
The authority of the Designees under this Statement shall continue until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and/or transactions in securities of the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Designees. The undersigned acknowledges that the Designees are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934. This Statement is not
intended to be a power of attorney as defined in the New York General
Obligations Law, Article 5, Title 15, Section 5-1501, and in the event this
Statement is determined to be a power of attorney under such statute, this
Statement shall not revoke any power of attorney previously executed by the
undersigned and shall not be revoked by any subsequent power of attorney unless
such subsequent power of attorney expressly provides that it revokes this
Statement by referring to the date and subject hereof.
Recent DCTH News
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
- Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call • Business Wire • 02/12/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:41:34 PM
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference • Business Wire • 01/27/2026 01:05:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/21/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:41:41 PM
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 01/09/2026 01:05:00 PM
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma • Business Wire • 12/31/2025 01:00:00 PM
